Key considerations for the development of novel mRNA candidate vaccines in LMICs: A WHO/MPP mRNA Technology Transfer Programme meeting report

Pierre-Stéphane Gsell; Birgitte Giersing; Sami Gottlieb; Annelies Wilder-Smith; Lindsey Wu; Martin Friede

doi:10.1016/j.vaccine.2023.10.027

Key considerations for the development of novel mRNA candidate vaccines in LMICs: A WHO/MPP mRNA Technology Transfer Programme meeting report

Vaccine. 2023 Nov 30;41(49):7307-7312. doi: 10.1016/j.vaccine.2023.10.027. Epub 2023 Nov 8.

Authors

Pierre-Stéphane Gsell¹, Birgitte Giersing², Sami Gottlieb², Annelies Wilder-Smith², Lindsey Wu², Martin Friede²

Affiliations

¹ World Health Organization, Geneva, Switzerland. Electronic address: gsellp@who.int.
² World Health Organization, Geneva, Switzerland.

PMID: 37949751
DOI: 10.1016/j.vaccine.2023.10.027

Abstract

The WHO/MPP mRNA Technology Transfer Programme, initiated in 2021, focuses on establishing mRNA vaccine manufacturing capacity in LMICs. On 17-21 April 2023, Programme partners were convened to review technology transfer progress, discuss sustainability aspects and promote mRNA product development for diseases relevant to LMICs. To help guide product development, this report introduces key considerations for for understanding the likelihood of technical and regulatory success and of policy development and procurement for mRNA vaccines to be developed and manufactured in LMICs. The report underscores the potential for LMICs to establish sustainable mRNA R&D pipelines.

Keywords: Local production; Technology transfer; mRNA vaccine R&D.

MeSH terms

Commerce
Developing Countries*
Technology Transfer
Vaccines*
World Health Organization

Substances

Vaccines

Grants and funding

001/WHO_/World Health Organization/International